亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial

无血性 临床终点 医学 临床试验 预测(人工智能) 心理学 随机对照试验 精神科 萧条(经济学) 内科学 安慰剂 精神分裂症(面向对象编程) 替代医学 病理 人工智能 计算机科学 经济 宏观经济学
作者
Sara Costi,Laurel S. Morris,Katherine A. Kirkwood,Megan Hoch,Morgan B. Corniquel,Brittany Vo‐Le,Tabish Iqbal,Nisha Chadha,Diego A. Pizzagalli,Alexis Estelle Whitton,Laura M. Bevilacqua,Manish K. Jha,Stefan Ursu,Alan C. Swann,Katherine Anne Collins,Ramiro Salas,Emilia Bagiella,Michael K. Parides,Emily R. Stern,Dan Vlad Iosifescu
出处
期刊:American Journal of Psychiatry [American Psychiatric Association]
卷期号:178 (5): 437-446 被引量:84
标识
DOI:10.1176/appi.ajp.2020.20050653
摘要

OBJECTIVE: Preclinical studies point to the KCNQ2/3 potassium channel as a novel target for the treatment of depression and anhedonia, a reduced ability to experience pleasure. The authors conducted the first randomized placebo-controlled trial testing the effect of the KCNQ2/3 positive modulator ezogabine on reward circuit activity and clinical outcomes in patients with depression. METHODS: Depressed individuals (N=45) with elevated levels of anhedonia were assigned to a 5-week treatment period with ezogabine (900 mg/day; N=21) or placebo (N=24). Participants underwent functional MRI during a reward flanker task at baseline and following treatment. Clinical measures of depression and anhedonia were collected at weekly visits. The primary endpoint was the change from baseline to week 5 in ventral striatum activation during reward anticipation. Secondary endpoints included depression and anhedonia severity as measured using the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Snaith-Hamilton Pleasure Scale (SHAPS), respectively. RESULTS: The study did not meet its primary neuroimaging endpoint. Participants in the ezogabine group showed a numerical increase in ventral striatum response to reward anticipation following treatment compared with participants in the placebo group from baseline to week 5. Compared with placebo, ezogabine was associated with a significantly larger improvement in MADRS and SHAPS scores and other clinical endpoints. Ezogabine was well tolerated, and no serious adverse events occurred. CONCLUSIONS: The study did not meet its primary neuroimaging endpoint, although the effect of treatment was significant on several secondary clinical endpoints. In aggregate, the findings may suggest that future studies of the KCNQ2/3 channel as a novel treatment target for depression and anhedonia are warranted.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
欢呼的馒头完成签到,获得积分10
2秒前
tigger完成签到 ,获得积分10
9秒前
zilicai的应助被冷阳采纳,获得10
21秒前
38秒前
如意大神完成签到,获得积分10
39秒前
43秒前
寒冷的月亮完成签到 ,获得积分10
46秒前
47秒前
落后的雪青完成签到,获得积分10
59秒前
1分钟前
1分钟前
YYY发布了新的文献求助10
1分钟前
Maestro_S的应助被Heaven采纳,获得10
1分钟前
1分钟前
MT完成签到,获得积分10
1分钟前
光亮的成败完成签到,获得积分10
1分钟前
1分钟前
快乐夜阑完成签到,获得积分10
1分钟前
完美世界的应助被Heaven采纳,获得10
1分钟前
1分钟前
Shicheng完成签到,获得积分10
1分钟前
zhiwei完成签到,获得积分10
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
腼腆的乘云完成签到,获得积分10
1分钟前
Ttimer发布了新的文献求助10
2分钟前
自觉康乃馨完成签到,获得积分10
2分钟前
ZYP完成签到,获得积分10
2分钟前
受伤若男完成签到,获得积分10
2分钟前
2分钟前
拉长的映波完成签到,获得积分10
2分钟前
yoshi发布了新的文献求助10
2分钟前
2分钟前
yoshi完成签到,获得积分10
3分钟前
搜集达人的应助被yoshi采纳,获得10
3分钟前
3分钟前
公冶愚志完成签到 ,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179920
求助须知:如何正确求助?哪些是违规求助? 9570103
关于积分的说明 21808354
捐赠科研通 7775701
什么是DOI,文献DOI怎么找? 3433193
关于科研通互助平台的介绍 2557347
邀请新用户注册赠送积分活动 2478918